MX2024007654A - Nuevos analogos del acido valproico y metodos de tratamiento medico que usan el mismo. - Google Patents
Nuevos analogos del acido valproico y metodos de tratamiento medico que usan el mismo.Info
- Publication number
- MX2024007654A MX2024007654A MX2024007654A MX2024007654A MX2024007654A MX 2024007654 A MX2024007654 A MX 2024007654A MX 2024007654 A MX2024007654 A MX 2024007654A MX 2024007654 A MX2024007654 A MX 2024007654A MX 2024007654 A MX2024007654 A MX 2024007654A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- medical treatment
- valproic acid
- novel analogs
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
- 229960000604 valproic acid Drugs 0.000 title 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
- C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2118559.0A GB2613900B (en) | 2021-12-20 | 2021-12-20 | Novel compounds and methods of use thereof |
| PCT/GB2022/053318 WO2023118846A1 (en) | 2021-12-20 | 2022-12-20 | Novel analogs of valproic acid and methods of medical treatment using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007654A true MX2024007654A (es) | 2024-07-04 |
Family
ID=84887257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007654A MX2024007654A (es) | 2021-12-20 | 2022-12-20 | Nuevos analogos del acido valproico y metodos de tratamiento medico que usan el mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250066282A1 (https=) |
| EP (1) | EP4452917A1 (https=) |
| JP (1) | JP2025500459A (https=) |
| KR (1) | KR20240152301A (https=) |
| CN (1) | CN118613464A (https=) |
| AU (1) | AU2022422574A1 (https=) |
| CA (1) | CA3242987A1 (https=) |
| GB (1) | GB2613900B (https=) |
| IL (1) | IL313669A (https=) |
| MX (1) | MX2024007654A (https=) |
| WO (1) | WO2023118846A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2644641A (en) * | 2024-09-24 | 2026-04-29 | Cereno Scient Ab | New methods |
| WO2026068561A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Valproic acid for use in treating pulmonary arterial hypertension |
| GB2644610A (en) * | 2024-09-27 | 2026-04-22 | Cereno Scient Ab | New methods |
| WO2026068552A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120071554A1 (en) * | 2008-10-28 | 2012-03-22 | Liu Julie F | Deuterated 2-propylpentanoic acid compounds |
| US20100143507A1 (en) * | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel |
| GB201417828D0 (en) * | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| RU2760304C2 (ru) * | 2016-04-08 | 2021-11-23 | Серено Сайентифик Аб | Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение |
-
2021
- 2021-12-20 GB GB2118559.0A patent/GB2613900B/en active Active
-
2022
- 2022-12-20 MX MX2024007654A patent/MX2024007654A/es unknown
- 2022-12-20 CA CA3242987A patent/CA3242987A1/en active Pending
- 2022-12-20 JP JP2024538134A patent/JP2025500459A/ja active Pending
- 2022-12-20 AU AU2022422574A patent/AU2022422574A1/en active Pending
- 2022-12-20 IL IL313669A patent/IL313669A/en unknown
- 2022-12-20 WO PCT/GB2022/053318 patent/WO2023118846A1/en not_active Ceased
- 2022-12-20 EP EP22839416.9A patent/EP4452917A1/en active Pending
- 2022-12-20 CN CN202280084449.3A patent/CN118613464A/zh active Pending
- 2022-12-20 US US18/721,594 patent/US20250066282A1/en active Pending
- 2022-12-20 KR KR1020247024372A patent/KR20240152301A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2613900A (en) | 2023-06-21 |
| CN118613464A (zh) | 2024-09-06 |
| IL313669A (en) | 2024-08-01 |
| KR20240152301A (ko) | 2024-10-21 |
| CA3242987A1 (en) | 2023-06-29 |
| GB2613900B (en) | 2024-01-17 |
| AU2022422574A1 (en) | 2024-07-18 |
| EP4452917A1 (en) | 2024-10-30 |
| US20250066282A1 (en) | 2025-02-27 |
| WO2023118846A1 (en) | 2023-06-29 |
| JP2025500459A (ja) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007654A (es) | Nuevos analogos del acido valproico y metodos de tratamiento medico que usan el mismo. | |
| PH12022552261A1 (en) | Crystalline hydrate of a jak inhibitor compound | |
| MX2023011576A (es) | Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos. | |
| MX2023009086A (es) | Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos. | |
| CR20210602A (es) | Compuestos de pirrolidina | |
| PH12021552134A1 (en) | Pyrazine derivative and application thereof in inhibiting shp2 | |
| GEP20257750B (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| MX2021012706A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| GEP20043265B (en) | Acetylenic alpha -Amino Acid-Based Sulfonamide Hydroxamic Acid TACE Inhibitors, Methods for Their Production, Pharmaceutical Compositions Containing the Same and Their Use for Inhibiting Pathological Conditions Mediated by TNF- Alpha Ferment (TACE) With Mammalians | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EP0489579A1 (en) | Peptidyl derivatives | |
| MX2023013147A (es) | Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8. | |
| EA201101308A1 (ru) | Применение ралфинамида для лечения биполярного расстройства | |
| MY209389A (en) | Use of bi853520 in cancer treatment | |
| MX2023006063A (es) | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. | |
| MX2017015456A (es) | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. | |
| MX2023004745A (es) | 1,4-diazepanonas biciclicas y sus usos terapeuticos. | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| US6235753B1 (en) | Inhibitors of the production of S-CD23 and the secretion of TNF | |
| MX2022000164A (es) | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. | |
| JOP20230090A1 (ar) | نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b |